Home
Live Updates
Bayer: BlueRocks Parkinsons Disease Cell Therapy Candidate Bemdaneprocel Gets FDA RMAT Designation : comparemela.com
Bayer: BlueRock's Parkinson's Disease Cell Therapy Candidate Bemdaneprocel Gets FDA RMAT Designation
LEVERKUSEN (dpa-AFX) - German pharmaceutical and life sciences major Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Thursday that its clinical stage cell therapy unit BlueRock Therapeutics LP's
Related Keywords
Germany ,
German ,
Christian Rommel ,
Bayer Pharmaceuticals Division ,
Head Of Research ,
More Such Health News ,
Drug Administration Regenerative Medicine Advanced Therapy ,
Bluerock Therapeutics ,
Drug Administration ,
Regenerative Medicine Advanced Therapy ,
Pharmaceuticals Division ,
Ihr Portfolio ,
comparemela.com © 2020. All Rights Reserved.